Clinical trial
PERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for…
NCT00432796 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, Other · Unknown status
Key facts
| NCT number | NCT00432796 |
|---|---|
| Title | PERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin. |
| Official title | A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2) |
| Lead sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, Other |
| Collaborators | Canadian Institutes of Health Research (CIHR) Pfizer Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Stroke |
| Intervention type | Drug, Other |
| Interventions | Dalteparin, Placebo |
| Enrollment | 1,473 |
| Start date | Dec 1, 2006 |
| Primary completion | Mar 1, 2019 |
| Completion | Dec 1, 2020 |
| First posted | Feb 8, 2007 |
| Last update posted | Feb 19, 2020 |
| Countries | Canada, India |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: